Literature DB >> 20402512

Small-animal PET imaging of human epidermal growth factor receptor positive tumor with a 64Cu labeled affibody protein.

Zheng Miao1, Gang Ren, Hongguang Liu, Lei Jiang, Zhen Cheng.   

Abstract

Epidermal growth factor receptor (EGFR) has become an attractive target for cancer molecular imaging and therapy. Affibody proteins against EGFR have been reported, and thus, we were interested in evaluating their potential for positron emission tomography (PET) imaging of EGFR positive cancer. An Affibody analogue (Ac-Cys-Z(EGFR:1907)) binding to EGFR was made through conventional solid phase peptide synthesis. The purified protein was site-specifically coupled with the 1,4,7,10-tetraazacyclododecane-1,4,7-tris-aceticacid-10-maleimidethylacetamide (maleimido-mono-amide-DOTA) to produce the bioconjugate, DOTA-Z(EGFR:1907). (64)Cu labeled probe (64)Cu-DOTA-Z(EGFR:1907) displayed a moderate specific activity (5-8 MBq/nmol, 22-35 microCi/microg). Cell uptake assays by pre-incubating without or with 300 times excess unlabeled Ac-Cys-Z(EGFR:1907) showed high EGFR-specific uptake (20% applied activity at 0.5 h) in A431 epidermoid carcinoma cancer cells. The affinity (K(D)) of (64)Cu-DOTA-Z(EGFR:1907) as tested by cell saturation analysis was 20 nM. The serum stability test showed excellent stability of the probe with >95% intact after 4 h of incubation in mouse serum. In vivo small-animal PET imaging showed fast tumor targeting, high tumor accumulation (approximately 10% ID/g at 1 h p.i.), and good tumor-to-normal tissue contrast of (64)Cu-DOTA-Z(EGFR:1907) spiked with a wide dose range of Ac-Cys-Z(EGFR:1907). Bio-distribution studies further demonstrated that the probe had high tumor, blood, liver, and kidney uptakes, while blood radioactivity concentration dropped dramatically at increased spiking doses. Co-injection of the probe with 500 microg of Ac-Cys-Z(EGFR:1907) for blocking significantly reduced the tumor uptake. Thus, (64)Cu-DOTA-Z(EGFR:1907) showed potential as a high tumor contrast EGFR PET imaging reagent. The probe spiked with 50 microg of Ac-Cys-Z(EGFR:1907) improved tumor imaging contrast which may have important clinical applications.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20402512     DOI: 10.1021/bc900515p

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  37 in total

1.  Alternative Non-Antibody Protein Scaffolds for Molecular Imaging of Cancer.

Authors:  Lawrence A Stern; Brett A Case; Benjamin J Hackel
Journal:  Curr Opin Chem Eng       Date:  2013-11       Impact factor: 5.163

2.  Use of (64)Cu-labeled fibronectin domain with EGFR-overexpressing tumor xenograft: molecular imaging.

Authors:  Benjamin J Hackel; Richard H Kimura; Sanjiv S Gambhir
Journal:  Radiology       Date:  2012-02-17       Impact factor: 11.105

3.  Robust surface coating for a fast, facile fluorine-18 labeling of iron oxide nanoparticles for PET/MR dual-modality imaging.

Authors:  Ziyan Sun; Kai Cheng; Fengyu Wu; Hongguang Liu; Xiaowei Ma; Xinhui Su; Yang Liu; Liming Xia; Zhen Cheng
Journal:  Nanoscale       Date:  2016-12-01       Impact factor: 7.790

4.  A novel 18F-labeled two-helix scaffold protein for PET imaging of HER2-positive tumor.

Authors:  Zheng Miao; Gang Ren; Lei Jiang; Hongguang Liu; Jack M Webster; Rong Zhang; Mohammad Namavari; Sanjiv S Gambhir; Faisal Syud; Zhen Cheng
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-07-15       Impact factor: 9.236

5.  Differential Receptor Tyrosine Kinase PET Imaging for Therapeutic Guidance.

Authors:  Eric Wehrenberg-Klee; N Selcan Turker; Pedram Heidari; Benjamin Larimer; Dejan Juric; José Baselga; Maurizio Scaltriti; Umar Mahmood
Journal:  J Nucl Med       Date:  2016-04-14       Impact factor: 10.057

6.  PET of EGFR expression with an 18F-labeled affibody molecule.

Authors:  Zheng Miao; Gang Ren; Hongguang Liu; Shibo Qi; Song Wu; Zhen Cheng
Journal:  J Nucl Med       Date:  2012-06-11       Impact factor: 10.057

7.  Radiolabeled affibody-albumin bioconjugates for HER2-positive cancer targeting.

Authors:  Susan Hoppmann; Zheng Miao; Shuanglong Liu; Hongguang Liu; Gang Ren; Ande Bao; Zhen Cheng
Journal:  Bioconjug Chem       Date:  2011-02-07       Impact factor: 4.774

8.  64Cu-Labeled Gp2 Domain for PET Imaging of Epidermal Growth Factor Receptor.

Authors:  Max A Kruziki; Brett A Case; Jie Y Chan; Elizabeth J Zudock; Daniel R Woldring; Douglas Yee; Benjamin J Hackel
Journal:  Mol Pharm       Date:  2016-10-10       Impact factor: 4.939

9.  18F-fluorobenzoate-labeled cystine knot peptides for PET imaging of integrin αvβ6.

Authors:  Benjamin J Hackel; Richard H Kimura; Zheng Miao; Hongguang Liu; Ataya Sathirachinda; Zhen Cheng; Frederick T Chin; Sanjiv S Gambhir
Journal:  J Nucl Med       Date:  2013-05-13       Impact factor: 10.057

10.  Affibody modified and radiolabeled gold-iron oxide hetero-nanostructures for tumor PET, optical and MR imaging.

Authors:  Meng Yang; Kai Cheng; Shibo Qi; Hongguang Liu; Yuxin Jiang; Han Jiang; Jinbo Li; Kai Chen; Huimao Zhang; Zhen Cheng
Journal:  Biomaterials       Date:  2013-01-21       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.